Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough

Amgen will pay $400m upfront and up to $850m in milestones

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.